Log In Sign up
The largest database of trusted experimental protocols

Pe labeled streptavidin

Manufactured by BD
Visit Supplier
Sourced in Netherlands

PE)-labeled streptavidin is a protein that can bind to the compound biotin. It is commonly used in various laboratory techniques and assays that require the detection or capture of biotinylated molecules.

Automatically generated - may contain errors

Lab products found in correlation

Biotin labeled protein l, by GenScript (2 mentions) Goat anti mouse f ab 2 antibodies anti fab, by Jackson ImmunoResearch (2 mentions) Cd3 cd28 dynabead, by Thermo Fisher Scientific (2 mentions) Fitc conjugated anti cd3, by Thermo Fisher Scientific (2 mentions) Macsmix tube rotator, by Miltenyi Biotec (1 mentions) Sulfo nhs lc biotin, by Abcam (1 mentions) Af 200 na, by R&D Systems (1 mentions) Lightning link streptavidin conjugation kit, by Abcam (1 mentions) Bira biotin protein ligase, by Avidity (1 mentions)

Close spelling variants of this product

Streptavidin-PE (163 citations) PE-CF594-labeled streptavidin (2 citations) PE-Cy7-labeled streptavidin (2 citations) Phycoerythrin (PE)–labeled streptavidin (2 citations)

10 protocols using pe labeled streptavidin

1

Quantifying CAR-T Cell Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols
To determine the percentage of infusion cells that expressed Hu19-CD828Z at the end of the 7 to 9-day cell production process, cell-surface CAR expression was detected by staining with biotin-labeled protein L (GenScript) followed by flow cytometry. The cells were also stained with phycoerythrin (PE)-labeled streptavidin (BD), anti-CD3, anti-CD4, and anti-CD8. The percentage of CAR-expressing (CAR+) T cells was calculated as the percentage of T cells in CAR-transduced cultures that stained with protein L minus the percentage of identically-cultured untransduced T cells from the same donor that stained with protein L48 .
Brudno J.N., Lam N., Vanasse D., Yueh-wei S., Rose J.J., Rossi J., Xue A., Bot A., Scholler N., Mikkilineni L., Roschewski M., Dean R., Cachau R., Youkharibache P., Patel R., Hansen B., Stroncek D.F., Rosenberg S.A., Gress R.E, & Kochenderfer J.N. (2020). Safety and feasibility of anti-CD19 CAR T cells with fully-human binding domains in patients with B-cell lymphoma. Nature medicine, 26(2), 270-280.
+ Open protocol
+ Expand
2

Cell Surface Biotinylation and IL-1α Secretion Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
The design of the IL-1α secretion assay was adapted based on a previous report50 (link). TH17 cells (1 × 106) were stained with 1 mg ml−1 of sulfo-NHS-LC-biotin (catalog no. ab145611, Abcam), incubated for 30 min at room temperature and then washed 3× with PBS (pH 8) supplemented with 100 mM glycine. The final washing of cells was performed with PBS supplemented with 0.5% bovine serum albumin. Cell surface biotinylation was validated with PE-labeled streptavidin (catalog no. 554061, BD Pharmingen). Purified anti-human IL-1α antibodies (AF-200-NA, R&D) were labeled with streptavidin using a Lightning-Link Streptavidin Conjugation kit (catalog no. ab102921, Abcam). For cytokine secretion, cells were stimulated with anti-CD3 and anti-CD28 for 72 h. The cells were collected and labeled with streptavidin-IL-1α and incubated for 24 h on the MACSmix tube rotator (Miltenyi Biotec). Recombinant IL-1α (Miltenyi Biotec) was added as a positive control. The cells were then stained with a PE-labeled IL-1α antibody (clone 364-3B3-14, BioLegend, 1:50).
Chao Y.Y., Puhach A., Frieser D., Arunkumar M., Lehner L., Seeholzer T., Garcia-Lopez A., van der Wal M., Fibi-Smetana S., Dietschmann A., Sommermann T., Ćiković T., Taher L., Gresnigt M.S., Vastert S.J., van Wijk F., Panagiotou G., Krappmann D., Groß O, & Zielinski C.E. (2023). Human TH17 cells engage gasdermin E pores to release IL-1α on NLRP3 inflammasome activation. Nature Immunology, 24(2), 295-308.
+ Open protocol
+ Expand
3

Synthesis and Characterization of Mart-1 Peptide Tetramer

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Mart-1 (27L)(ELAGIGILTV) peptide was synthesized by Biosynthesis Inc. 96 self peptides (56 (link)) were also synthesized by Biosynthesis Inc. and suspended in water to 1 mM concentration. Allophycocyanin (APC) anti-mouse TCRβ constant (Clone H57-597) and phycoerythrin (PE) anti-mouse CD3ε (Clone 145-2C11) antibodies were from eBiosciences; For Mart-1 (27L)/HLA-A2 tetramer production, HLA-A2 heavy chain with a biotinylation sequence at C-terminus (kindly provided from Dr. Cerundolo, John Radcliffe Hospital, UK) and human β2M were purified as inclusion body from E. coli. The complexes were refolded in vitro with Mart-1 (27L) peptide as previously described (9 , 57 (link), 58 (link)). The folded protein was concentrated and biotinylated with BirA Biotin Protein Ligase (Avidity) accordingly to manufacturer’s instructions. Protein purification and tetramer production were performed as previously described (59 (link)) by adding PE-labeled streptavidin (BD Pharmingen) in 1/10 volume aliquots to the biotinylated monomeric complexes in a 1 to 4 molar ratio. All the tetramer stains were done at 4°C.
Malecek K., Grigoryan A., Zhong S., Gu W.J., Johnson L.A., Rosenberg S.A., Cardozo T, & Krogsgaard M. (2014). Specific increase in potency via structure-based design of a T cell receptor. Journal of immunology (Baltimore, Md. : 1950), 193(5), 2587-2599.
+ Open protocol
+ Expand
4

Pharmacokinetics of ASKP1240 in Monkeys

Check if the same lab product or an alternative is used in the 5 most similar protocols
ASKP1240 was administered intravenously once at dose levels of 0 (placebo), 0.1, 1, 3 and 10 mg/kg to four male cynomolgus monkeys per group. Sampling points were set between days −11 and 49 according to dose level. The collected blood samples were lysed and stained with biotinylated ASKP1240 plus PE-labeled streptavidin (BD) and allophycocyanin-labeled anti-CD20 mAb (clone 2H7; BD). The geoMFI of PE in CD20+ lymphocytes was monitored by flow cytometory. ASKP1240 was also determined by an ELISA, as described before 28 (link).
Okimura K., Maeta K., Kobayashi N., Goto M., Kano N., Ishihara T., Ishikawa T., Tsumura H., Ueno A., Miyao Y., Sakuma S., Kinugasa F., Takahashi N, & Miura T. (2014). Characterization of ASKP1240, a Fully Human Antibody Targeting Human CD40 With Potent Immunosuppressive Effects. American Journal of Transplantation, 14(6), 1290-1299.
+ Open protocol
+ Expand
5

Alloantibody Detection in Transplant

Check if the same lab product or an alternative is used in the 5 most similar protocols
IgM and IgG donor-reactive alloantibodies were retrospectively measured by flow cytometry using archived frozen donor peripheral blood lymphocytes and recipient serum samples. Antibody binding was revealed using PE-labeled goat antihuman IgM antibodies (Thermofisher, MA) or biotin-labeled goat antimonkey IgG (Fcγ specific) antibodies (Nordic, Netherlands) followed by PE-labeled streptavidin (BD Biosciences—Pharmingen). FITC-labeled antihuman CD3 (BD Biosciences, CA) was added to gate on T cells. Alloantibody reactivity was defined as an increase of more than 10% in the proportion of IgM- or IgG-positive donor cells relative to donor serum before transplant.
Shockcor N., Buckingham E.B., Hassanein W., Dhru U., Khalifeh A., Uluer M., Woodall J., Brazio P., Drachenberg C., Nam A.J, & Barth R.N. (2021). Vascularized Bone Marrow Cellular Depletion or Discontinuity Abrogates Protection of Vascularized Composite Allografts in Nonhuman Primates. Transplantation Direct, 7(2), e659.
+ Open protocol
+ Expand
6

Quantification of CAR+ T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
This method was used to determine the percentage of CAR+ T cells among infusion FMC63–28Z T cells. For each patient, a sample of FMC63–28Z-transduced cells was stained with biotin-labeled polyclonal goat anti-mouse-F(ab)2 antibodies (anti-Fab, Jackson Immunoresearch) to detect the CAR. A sample of untransduced identically-cultured cells from the same donor was stained with the anti-Fab antibodies as a control. Next, the cells were all stained with phycoerythrin (PE)-labeled streptavidin (BD), anti-CD3, anti-CD4, and anti-CD8. The percentage of FMC63–28Z-transduced T cells that expressed the CAR (CAR+ T cells) was calculated by subtracting the percentage of untransduced CD3+ cells that were stained with the anti-Fab antibodies from the percentage of FMC63–28Z-transduced CD3+ cells that were stained with the anti-Fab antibodies. Product-release criteria for FMC63–28Z T cells are in (Supplementary Table 6).
Brudno J.N., Lam N., Vanasse D., Yueh-wei S., Rose J.J., Rossi J., Xue A., Bot A., Scholler N., Mikkilineni L., Roschewski M., Dean R., Cachau R., Youkharibache P., Patel R., Hansen B., Stroncek D.F., Rosenberg S.A., Gress R.E, & Kochenderfer J.N. (2020). Safety and feasibility of anti-CD19 CAR T cells with fully-human binding domains in patients with B-cell lymphoma. Nature medicine, 26(2), 270-280.
+ Open protocol
+ Expand
7

Quantifying CAR-T Cell Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols
To determine the percentage of infusion cells that expressed Hu19-CD828Z at the end of the 7 to 9-day cell production process, cell-surface CAR expression was detected by staining with biotin-labeled protein L (GenScript) followed by flow cytometry. The cells were also stained with phycoerythrin (PE)-labeled streptavidin (BD), anti-CD3, anti-CD4, and anti-CD8. The percentage of CAR-expressing (CAR+) T cells was calculated as the percentage of T cells in CAR-transduced cultures that stained with protein L minus the percentage of identically-cultured untransduced T cells from the same donor that stained with protein L48 .
Brudno J.N., Lam N., Vanasse D., Yueh-wei S., Rose J.J., Rossi J., Xue A., Bot A., Scholler N., Mikkilineni L., Roschewski M., Dean R., Cachau R., Youkharibache P., Patel R., Hansen B., Stroncek D.F., Rosenberg S.A., Gress R.E, & Kochenderfer J.N. (2020). Safety and feasibility of anti-CD19 CAR T cells with fully-human binding domains in patients with B-cell lymphoma. Nature medicine, 26(2), 270-280.
+ Open protocol
+ Expand
8

Quantification of CAR+ T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
This method was used to determine the percentage of CAR+ T cells among infusion FMC63–28Z T cells. For each patient, a sample of FMC63–28Z-transduced cells was stained with biotin-labeled polyclonal goat anti-mouse-F(ab)2 antibodies (anti-Fab, Jackson Immunoresearch) to detect the CAR. A sample of untransduced identically-cultured cells from the same donor was stained with the anti-Fab antibodies as a control. Next, the cells were all stained with phycoerythrin (PE)-labeled streptavidin (BD), anti-CD3, anti-CD4, and anti-CD8. The percentage of FMC63–28Z-transduced T cells that expressed the CAR (CAR+ T cells) was calculated by subtracting the percentage of untransduced CD3+ cells that were stained with the anti-Fab antibodies from the percentage of FMC63–28Z-transduced CD3+ cells that were stained with the anti-Fab antibodies. Product-release criteria for FMC63–28Z T cells are in (Supplementary Table 6).
Brudno J.N., Lam N., Vanasse D., Yueh-wei S., Rose J.J., Rossi J., Xue A., Bot A., Scholler N., Mikkilineni L., Roschewski M., Dean R., Cachau R., Youkharibache P., Patel R., Hansen B., Stroncek D.F., Rosenberg S.A., Gress R.E, & Kochenderfer J.N. (2020). Safety and feasibility of anti-CD19 CAR T cells with fully-human binding domains in patients with B-cell lymphoma. Nature medicine, 26(2), 270-280.
+ Open protocol
+ Expand
9

T cell transduction and activation

Check if the same lab product or an alternative is used in the 5 most similar protocols
T cells selected and activated with CD3/CD28 Dynabeads (Invitrogen) from healthy donors were transduced with vector stocks harvested from iCELLis Nano bioreactors or cell factories at various dilutions using T cells at 1×106 per mL. Transduction efficiency was determined by FACS analysis using FITC conjugated anti-CD3 (invitrogen), biotin-conjugated goat anti-mouse antibody followed by PE-labeled streptavidin (Becton Dickinson) for CAR.
Wang X., Olszewska M., Qu J., Wasielewska T., Bartido S., Hermetet G., Sadelain M, & Rivière I. (2015). Large-scale Clinical-grade Retroviral Vector Production in a Fixed-Bed Bioreactor. Journal of Immunotherapy (Hagerstown, Md. : 1997), 38(3), 127-135.
+ Open protocol
+ Expand
10

Transduction of T Cells with CAR

Check if the same lab product or an alternative is used in the 5 most similar protocols
T cells selected and activated with CD3/CD28 Dynabeads (Invitrogen) from healthy donors were transduced with vector stocks harvested from iCELLis Nano bioreactors or cell factories at various dilutions using T cells at 1E6/mL. Transduction efficiency was determined by FACS analysis using FITC conjugated anti-CD3 (invitrogen), biotin-conjugated goat anti-mouse antibody followed by PE-labeled streptavidin (Becton Dickinson) for chimeric antigen receptor.
Wang X., Olszewska M., Qu J., Wasielewska T., Bartido S., Hermetet G., Sadelain M, & Rivière I. (2015). Large-scale Clinical-grade Retroviral Vector Production in a Fixed-Bed Bioreactor. Journal of Immunotherapy (Hagerstown, Md. : 1997), 38(3), 127-135.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!